Phuturdex › Diseases › Peripheral Nervous System Diseases
Drugs in development · updated 30 October 2026
Peripheral Nervous System Diseases: drugs in development
As of 30 October 2026 there are 13 active clinical trials (recruiting or ongoing, phases I–III) on 16 drugs for peripheral Nervous System Diseases. 8 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DLBS1033 | II–III | 1 | NCT07475065 |
| Mecobalamin | III | 1 | NCT07423390 |
| AFA-281 | II | 1 | NCT06649747 |
| Halneuron | II | 1 | NCT06848348 |
| Nicotinamide ribosideNicotinamide ribonucleoside | II | 1 | NCT04112641 |
| PT-112 | II | 1 | NCT05104736 |
| Sacituzumab TirumotecanSKB264 | II | 1 | NCT07662863 |
| GB-4362 | I | 1 | NCT07484022 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PregabalinLyrica Cr®, Lyrica® | III | 2 | NCT07712913 |
| MemantineNamenda, Memantine Mylan® | II–III | 1 | NCT07504198 |
| RosuvastatinEzallor Sprinkle®, Crestor® | II–III | 1 | NCT07504198 |
| AmantadineGocovri, Osmolex Er® | II | 1 | NCT07889115 |
| DesloratadineDesloratodine, Clarinex® | II | 1 | NCT07109817 |
| DuloxetineDrizalma Sprinkle®, Cymbalta® | II | 1 | NCT06614322 |
| Enfortumab VedotinPadcev® | I | 1 | NCT07484022 |
| PembrolizumabKEYTRUDA, MK-3475 | I | 1 | NCT07484022 |
Sorted by most advanced phase and number of active trials.
All 16 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Neurofibromatosis 1 28 drugs
- Chronic inflammatory demyelinating polyradiculoneuropathy 23 drugs
- Neurofibrosarcoma 24 drugs
- Neuralgia 21 drugs
- Plexiform neurofibroma 12 drugs
- Sarcoma 204 drugs
- Diabetic Neuropathies 12 drugs
- Pain 75 drugs
- Osteosarcoma 101 drugs
- Synovial sarcoma 33 drugs
- Neuroblastoma 95 drugs
- Familial amyloid neuropathy 4 drugs
Broader categories
- Nervous System Diseases 39 drugs
- Neuromuscular disease 14 drugs
- Neoplasm 671 drugs
- Skin disease 34 drugs
- Skin and connective tissue diseases 3 drugs
- Neurologic Manifestations 15 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D010523 “Peripheral Nervous System Diseases”.